Dossier
Global Benchmark for Efficient Drug Pricing (GLOBE)
Coverage of Global Benchmark for Efficient Drug Pricing (GLOBE) in the Nexus archive.
- STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds
Excluding rare disease treatments from Medicare drug-pricing pilots would eliminate significant savings, according to a Harvard University researcher. Biotech companies are lobbying the Trump administration to exclude these treatments from the Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) pilots, which aim to lower drug prices to levels in other wealthy nations.